Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors

NCT00124332 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00124332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00124332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
October 31, 2007
Enrollment
839 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

coronary atherosclerosis